We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.1%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.42B
AUM Growth
-$747M
Cap. Flow
-$166M
Cap. Flow %
-6.88%
Top 10 Hldgs %
25.87%
Holding
144
New
14
Increased
42
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$54.6M
2
APLT
Applied Therapeutics
APLT
+$33.4M
3
CNC icon
Centene
CNC
+$31.6M
4
BPMC
Blueprint Medicines
BPMC
+$22.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.1M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$106M
2
UNH icon
UnitedHealth
UNH
+$80.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$64.2M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$35.2M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 95.03%
2 Consumer Staples 1.05%
3 Consumer Discretionary 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
76
DELISTED
Zogenix, Inc.
ZGNX
$9.89M 0.41%
400,000
+150,000
+60% +$5.46M
FOLD
77
DELISTED
Amicus Therapeutics
FOLD
$9.24M 0.38%
1,000,000
– –
RIGL icon
78
Rigel Pharmaceuticals
RIGL
$774M
$8.58M 0.35%
550,000
+210
+0% +$4.47K
TVTX icon
79
Travere Therapeutics
TVTX
$5.81B
$8.39M 0.35%
575,000
– –
TBIO
80
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$8.22M 0.34%
825,000
-125,000
-13% -$1.02M
PPD
81
DELISTED
PPD, Inc. Common Stock
PPD
$8.02M 0.33%
+450,000
New +$11.3M
CGEN icon
82
Compugen
CGEN
$225M
$7.99M 0.33%
1,100,000
– –
MYOK
83
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$7.74M 0.32%
165,000
+5,000
+3% +$320K
RYTM icon
84
Rhythm Pharmaceuticals
RYTM
$7.91B
$7.61M 0.31%
500,000
+155,000
+45% +$2.78M
CNST
85
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$7.34M 0.3%
233,500
– –
MRSN
86
DELISTED
Mersana Therapeutics
MRSN
$7.19M 0.3%
49,320
– –
ELVN icon
87
Enliven Therapeutics
ELVN
$4.26B
$7.15M 0.3%
+111,484
New +$7.1M
BHVN
88
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.81M 0.28%
200,000
– –
QTTB icon
89
Q32 Bio
QTTB
$453M
$6.61M 0.27%
23,611
– –
XENT
90
DELISTED
Intersect ENT, Inc
XENT
$5.92M 0.25%
500,000
-300,000
-38% -$6.65M
XENE icon
91
Xenon Pharmaceuticals
XENE
$6.16B
$5.67M 0.23%
+500,000
New +$7.12M
DVAX
92
DELISTED
Dynavax Technologies
DVAX
$5.56M 0.23%
1,575,000
– –
PRTA icon
93
Prothena Corp
PRTA
$470M
$5.35M 0.22%
+500,000
New +$6.06M
STAA icon
94
STAAR Surgical
STAA
$1.25B
$5M 0.21%
+155,000
New +$5.22M
TMO icon
95
Thermo Fisher Scientific
TMO
$223B
$4.96M 0.21%
17,500
-63,500
-78% -$20M
CHMA
96
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.93M 0.2%
1,350,000
+190,000
+16% +$843K
SPRO icon
97
Spero Therapeutics
SPRO
$71.2M
$4.89M 0.2%
605,000
+80,000
+15% +$705K
ALLO icon
98
Allogene Therapeutics
ALLO
$742M
$4.86M 0.2%
+250,000
New +$5.95M
PRTK
99
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.81M 0.2%
1,526,310
+1,151,310
+307% +$4.25M
AKRO
100
DELISTED
Akero Therapeutics
AKRO
$4.77M 0.2%
225,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rock Springs Capital Management held 144 positions worth $2.42B, down 24% from $3.16B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management withdrew a net $166M in Q1 2020, closing 13 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Rock Springs Capital Management opened a new position in Biogen worth $56.9M.

  • Rock Springs Capital Management's largest Q1 2020 buy was Biogen: 180,000 shares worth $56.9M.
  • Rock Springs Capital Management added most to Applied Therapeutics in Q1 2020, an estimated $33.4M increase.
  • Rock Springs Capital Management's biggest Q1 2020 reduction was UnitedHealth, cutting an estimated $80.1M.
  • Rock Springs Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $106M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.42B portfolio in Q1 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q1 2020.
  • Rock Springs Capital Management's portfolio value fell 24% quarter-over-quarter to $2.42B.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.